DHHS Guidelines Highlight Importance of Achieving Suppression When Choosing New ARV Agents1
ARV regimen considerations for treatment-experienced patients

suppression is essential
The primary goal of treatment for ART-experienced patients with drug resistance experiencing virologic failure is to establish suppression.

Potency is critical
For patients with virologic failure, consider expected potency of additional agent(s), taking into account the patient's ART history, resistance, and availability of a new MOA.

INCLUDES 2-3 FULLY ACTIVE AGENTS
For multiple or extensive drug resistance with few treatment options, a new regimen should include at least 2, and preferably 3, fully active agents (including those with novel mechanisms of action). If choosing a regimen with fewer than 3 fully active drugs, include as many fully active drugs as possible, along with potentially partially active drugs.

Beware of cross-resistance
The use of a new drug does not ensure that it will be fully active due to the potential for cross-resistance among drugs from the same class.